Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="Bispecific antibodies are highly potent molecules that facilitate T cell-mediated killing of tumour cells."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="Bispecific antibodies are highly potent molecules that facilitate T cell-mediated killing of tumour cells."> <meta property="og:title" content="Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment"> <meta name="twitter:description" content="Bispecific antibodies are highly potent molecules that facilitate T cell-mediated killing of tumour cells."> <meta name="twitter:title" content="Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-T-Cell-Engagers-and-Primers-scaled.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-T-Cell-Engagers-and-Primers-scaled.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> NextGen Therapeutics | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment </h1> <div class="byline"> Edited by Tia Byer | 28 February 2022 </div> <div class="abstract"> Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies? </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Bispecific-T-Cell-Engagers-and-Primers-scaled.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap">  <p>T cell-based bispecific antibody immunotherapies have reshaped treatment paradigms across various cancer types. The global bispecific antibody market is expected to increase to 25 billion USD by 2028, with the number of commercially available products projected to increase by 150% over the next 5 to 6 years. Harnessing the capabilities of immune cells, especially T cells, to enhance anti-tumour activity is a widely adopted strategy in the clinical management of cancer. However, challenges remain, as a wide cross-section of the population do not respond to pre-established cancer treatments, with tumours either refracting or developing resistance. There are also economic and logistical hurdles associated with scaling-up and considerable risk in systematic stimulation, which can lead to toxicity. Nevertheless, stimulating T cells can lead to transformational clinical benefits for cancer patients. Current trends in development include redirecting, reinvigorating, and activating T cells for optimal results. Key players in the field include Abbvie, Alligator Biosciences, Amgen, Bristol-Myers Squibb, F-star, Genmab, Ichnos, Janssen, Regeneron, and Roche.</p>   <h2 id="h-bispecific-t-cell-engagers-background-and-industry-overview">Bispecific T Cell Engagers - Background and Industry Overview:</h2>   <p>Bispecific antibodies are highly potent molecules that facilitate T cell-mediated killing of tumour cells. Simultaneously binding to tumour antigen and CD3e chains results in the activation of the T cell receptor. Subsequent T cell engagement includes the activation and killing of tumour cells by releasing cytotoxic granules. T cells start to proliferate and expand at the activation site, releasing cytokine and chemokine, which leads to the recruitment of additional T cells. Christian Klein, Site Head Roche Innovation Centre Zurich, explains how “T cell bispecifics are very potent and can mediate so-called serial killing of tumour cells”. He continued, “notably, they can be independent of specificity and the action and differentiation status of T cells”. A major advantage of T cell bispecific antibodies is that they can overcome the various escape mechanisms of cancer cells.</p>   <ul><li><a href="https://oxfordglobal.com/biologics/resources/bispecific-antibodies-formats-and-applications/" target="_blank" rel="noreferrer noopener">Read our Discussion Group Report Addressing the Future of Bispecific and Multi-Specific Antibodies</a></li><li><a href="https://oxfordglobal.com/biologics/resources/a-new-cancer-killing-bispecific-antibody-working-toward-the-clinic-in-2022/" target="_blank" rel="noreferrer noopener">Check out our Commentary Article Analysing Alligator Bioscience AB and Apteov Therapeutics Inc's Joint Bispecific Antibody </a></li></ul>   <p></p>   <p>“The field has now essentially moved on to IgG-based T cell bispecific antibodies, with numerous platforms in clinical trials across the industry,” Klein continued. Upcoming platforms include Amgen’s Fc-BiTE, classical 1+1 IgG based T cell bispecifics like Genentech’s TDB platform applied in Mosunetuzumab and Cevostamab, Genmab’s Duobody platform used for example in Epcoritamab with Abbvie or in Teclistamab and Talquetamb with Janssen, Regeneron’s common light chain 1+1 IgG applied to Odronextamab, and an IgG-scFv platform applied for instance by Xencor for Plamotamab with Janssen. Roche has developed its own differentiated 2+1 TCB platform applied e.g. for development of glofitamab and cibisatamab making use of bivalent binding to tumour antigens. </p>   <blockquote class="wp-block-quote"><p><em><strong>Peter Ellmark, Chief Scientific Officer at Alligator Bioscience concurs, explaining how, “there is a great and rapidly increasing need for ... therapies that can expand the number and quality of tumour infiltrating T cells”.</strong></em></p></blockquote>   <p>According to Klein, “the interesting aspect of the different T cell bispecific antibody formats making their way to the clinic, is that they essentially enable you to mimic CAR T cell functioning by using off the shelf reagents”. Peter Ellmark, Chief Scientific Officer at Alligator Bioscience concurs, explaining how, “there is a great and rapidly increasing need for such therapies that can expand the number and quality of tumour infiltrating T cells”.</p>   <h2>A Promising Landscape: 3 Industry Case-Studies</h2>   <p>From T cell priming, redirecting activated T cells, and endogenous and synthetic immunity, the possibilities are numerous. To find out more, we sat down with 3 leading pharmaceutical companies paving the way with their novel T-cell bispecific antibodies treatment strategies.</p>   <p><strong>1.) Roche: ‘Roche-Genentech Cancer Immunotherapy Strategy’</strong></p>   <p>Founded in 1896, Roche is a Swiss multinational healthcare leader that focuses on delivering life-saving pharmaceuticals and cutting-edge diagnostics. Roche-Genentech’s strategy relies on a multi-functional approach to cancer immunotherapy, which makes use of <strong>endogenous immunity approaches</strong>, that rely on pre-existing T cells that have been formed by the body’s immune system to attack the cancer for example by blocking the PD-L1 checkpoint inhibitor or other notable checkpoint inhibitors including TIGIT (tiragolumab), or by simultaneously blocking PD-1 and LAG-3 with a bispecific antibody.</p>   <p>In addition, the <strong>synthetic immunity approach</strong> is a direction in which Roche and Genentech have various T cell engaging bispecific antibodies in development such as cibisatamab, glofitamab, mosunetuzumab or cevostamab. Roche’s portfolio also harnesses targeted immunomodulators to further boost the activity of T cells, and examples of this include FAP-4-1BBL and CD19-4-1BBL fusion proteins as well as a PD1-targeted IL2v immunocytokine. With multiple engineered antibody projects in the clinical study phase, Roche is set to make big waves in the immunotherapy field.</p>   <p><strong>2.) Alligator Biosciences: ‘Neo-X-Prime’</strong></p>   <p>Alligator Biosciences is a Swedish-based clinical-stage biotechnology company entirely focused on immuno-oncology since 2008. Their pipeline includes novel mono- and bispecific antibody technology platforms and have been listed on the Nasdaq Stockholm exchange since 2016. Neo-X-Prime is a neoantigen cross-presentation-inducing bispecific CD40 antibody created by Alligator Biosciences to enhance tumour-specific T cell priming. It is a tetravalent format consisting of two CD40 binding domains and two tumour-antigens. The Fc part of the bispecific is a silenced IgG1 which, according to Ellmark, “is critical when trying to avoid any interaction with Fc gamma receptors”. The CD 40 agonist in this antibody depends on cross-linking to induce a strong immune activation, meaning that it will only activate CD 40 when it binds to tumour antigens simultaneously.</p>   <div class="wp-block-image"><figure class="aligncenter size-full"><img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Neo-X-Prime.jpg" alt="T cell bispecific antibodies at Alligator Biosciences" class="wp-image-23369"></figure></div>   <p>Alligator’s first-generation Neo-X compound is a technology platform designed and developed to enhance the priming, quantity, and quality of tumour specific T cells. Ellmark explains how “Neo-X provides an opportunity to drive the expansion of T cells which allows for treatment of indications that either has primary or secondary resistance to PD-1 and other checkpoint inhibitors”. Additionally, the CD40 antibodies act on myeloid cells and macrophages and can potentially remodel the tumour microenvironment. By mediating cancer activity, Neo-X activates dendritic cells and promotes the uptake of tumour exosomes carrying personal neoantigens. APCs then cross-present neoantigens and activate T cells which leads to the killing of tumour cells. CD40 was identified as the optimal DC target for inducing strong T cell internalisation and priming to tumour antigens with improved functional activity discernible when linked to the antigen.</p>   <p><strong>3.) F-star Therapeutics: ‘FS222’</strong></p>   <p>F-star is a clinical stage biopharmaceutical company founded in 2006 with an advanced pipeline of multiple immuno-oncology programs dedicated to creating a paradigm shift in cancer therapy. Its proprietary technology introduces mutations into the Fc domain of an antibody to then generate an Fc antigen-binding domain or ‘Fcab’. By subcloning the Fcab into a standard monoclonal antibody construct, a bispecific antibody, termed a mAb<sup>2 </sup>antibody, is established, which maintains the bivalent nature of the Fab arm and introduces the dual Fcab binding domains. </p>   <blockquote class="wp-block-quote"><p><strong><em>In the coming years, we can expect to witness new product launches globally and favourable policies implemented to aid in the fight against cancer.</em></strong></p></blockquote>   <p>FS222 is a clinical-stage programme and tetravalent bispecific antibody designed for optimal T cell activation with minimal toxicity. Ryan Fiehler, Associate Director of Discovery at F-star, stated that “the purpose of FS222 is to redirect activated T cells to the tumour”. FS222 simultaneously “releases the brake” on immune control of cancer by blocking the PD-1/PD-L1 pathway and “hits the gas” on immune activation by stimulating the CD137 pathway. The bispecific antibody also induces potent PD-L1-dependent T cell activation, and according to Fiehler, “shows strong anti-tumour activity in multiple models”.</p>   <div class="wp-block-image"><figure class="aligncenter size-full is-resized"><img src="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg?width=440&height=270&name=Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg" alt="T cell-based bispecific antibody immunotherapies " class="wp-image-23373" width="440" height="270" srcset="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg?width=220&height=135&name=Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg 220w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg?width=440&height=270&name=Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg 440w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg?width=660&height=405&name=Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg 660w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg?width=880&height=540&name=Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg 880w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg?width=1100&height=675&name=Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg 1100w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Biologics/Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg?width=1320&height=810&name=Fstars-Proprietary-Technology-Bispecific-IgG-with-Dual-Bivalency.jpg 1320w" sizes="(max-width: 440px) 100vw, 440px"></figure></div>   <p>What is most promising about FS222 is the potential to avoid dose-limiting hepatoxicity at therapeutic doses. In designing the technology platform, F-star established a mechanism of action that harnesses, as Fiehler explained, “the three C’s: crosslinking, clustering, and conditionality”. Resulting T- cell activation, proliferation, and eventual redirection occur to ensure tumour killing disease control. So far, F-star has found that FS222 bound CD137 and PD-L1 simultaneously and tetravalently to elicit potent <em>in vitro </em>T cell activation only in the presence of PD-L1. Studies using different valency combinations showed that tetravalent binding provided superior activity in terms of efficacy and potency in <em>in-vitro </em>assays. Therefore, FS222 presents a unique opportunity versus high affinity CD137 binding bispecific molecules by opening a broad therapeutic window.</p>   <p><strong>Future Outlooks:</strong></p>   <p>With a crowded pipeline, the bispecific antibody market will continue to grow at a double-digit rate. The rise in the number of cancer and chronic diseases, along with various government initiatives and cross-industry collaborations will see the field go (and grow) from strength to strength. In the coming years, we can expect to witness new product launches globally and favourable policies implemented to aid in the fight against cancer. At <a href="https://oxfordglobal.com/" target="_blank" rel="noreferrer noopener">Oxford Global</a>, we have our eyes firmly peeled and look forward to the latest developments as they unfold.</p>  <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-event"> <h3 class="center">Related Events</h3> For more on this topic, you may be interested in our upcoming <a href="/nextgen-biomed/events/nextgen-biomed-2025">Proteins & Antibodies</a> </div> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/T-Cell-Engagement-and-Activation-New-Developments.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments"> <h4> T Cell Engagement and Activation: New Developments </h4> <div class="abstract"> As cancer treatments continue to develop, bispecific cell engagers are revolutionising this therapeutic landscape. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/t-cell-engagement-and-activation-new-developments" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Bispecific-T-Cell-Engagers-Synthetic-Immunity-Halting-Immune-Escape-rotated.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape"> <h4> Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape </h4> <div class="abstract"> Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/bispecific-t-cell-engagers-and-synthetic-immunity-circumventing-immune-escape" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/harnessing-bispecific-t-cell-engagers-and-t-cell-primers-in-cancer-treatment"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999077"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999077", "legacyPageId": "hubdb-177607186815-30817717-181072999077", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "17b19e93-a802-4258-8aeb-ebad2ac35f55", ticks: 1732665961111, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999077", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999077", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment